Compare PBH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | NUVB |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2005 | N/A |
| Metric | PBH | NUVB |
|---|---|---|
| Price | $62.05 | $9.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $86.40 | $10.63 |
| AVG Volume (30 Days) | 500.4K | ★ 6.8M |
| Earning Date | 02-05-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $1,110,479,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $609.55 |
| Revenue Next Year | $2.50 | $197.91 |
| P/E Ratio | $15.27 | ★ N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $57.25 | $1.54 |
| 52 Week High | $90.04 | $9.53 |
| Indicator | PBH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 74.81 |
| Support Level | $60.98 | $8.13 |
| Resistance Level | $62.92 | $8.95 |
| Average True Range (ATR) | 1.45 | 0.54 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 79.70 | 96.87 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.